arrow
S

Sandra Sauer

universitätsklinikum heidelberg
H指数:19
被引数:1,321

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

2016年至2022年间EBMT中心中,17p缺失的骨髓瘤患者在接受AHSCT时,细胞遗传学异常的累积效应对其预后的影响

2026-09-050
OAAI
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis

标准护理方案中,在早期与较晚期治疗线中使用cilta-cabtagene autoleucel治疗复发或难治性多发性骨髓瘤:一项全国注册登记分析

2026-05-200
OAAI
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma

结构化全身MRI突显了复发/难治性多发性骨髓瘤临床相关疾病模式的变化。

Leukemia
IF13.4
2025-12-220
OAAI
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma

基于基线MRI的自动放射组学模型,用于预测多发性骨髓瘤的治疗反应和微小残留病灶

2025-10-100
OA
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 Trial

验证用于量化多发性骨髓瘤患者四肢骨骼骨髓的新型低剂量CT方法:来自Phase 3 GMMG-HD7试验[18F]FDG PET/CT亚研究的初步结果

2025-10-010
OA
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

缓解转换驱动多发性骨髓瘤CAR T细胞疗法的结局:来自DRST登记研究的分析

Blood
IF23.1
2025-06-140
OA
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

桥接强度与多发性骨髓瘤患者接受BCMA CAR-T疗法后的造血恢复受损相关

2025-04-250
OAAI
MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

流式细胞术和FDG-PET/CT在GMMG HD7研究治疗的多发性骨髓瘤患者诱导治疗后反应评估中的微小残留病灶检测

BLOOD
IF23.1
2024-11-050
PRE
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

EASIX指导的复发/难治性多发性骨髓瘤中使用ide-cel进行CAR T细胞治疗后并发症和结局的风险分层

2024-10-071
OAAI
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/ Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation

Idecabtagene Vicleucel在先前接受异基因干细胞移植的复发/难治性骨髓瘤患者中耐受性良好且有效

2023-10-014
OAAI
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
2023-08-1716
OAAI
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma

基于人工智能的工具在[18F]FDG PET/CT中的应用:用于评估多发性骨髓瘤的骨髓受累情况

2023-07-2611
OAAI
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics

使用深度学习和放射组学预测多发性骨髓瘤患者MRI的骨髓活检结果

2023-05-2212
PRE